SARTORIUS (SARTF)
(Delayed Data from OTC)
$207.46 USD
0.00 (0.00%)
Updated Sep 5, 2024 03:59 PM ET
5-Strong Sell of 5 5
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SARTF 207.46 0.00(0.00%)
Will SARTF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SARTF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SARTF
SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know
SARTORIUS (SARTF) Q3 Earnings Lag Estimates
SARTF: What are Zacks experts saying now?
Zacks Private Portfolio Services
SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?
SARTORIUS (SARTF) Q3 Earnings and Revenues Top Estimates
Dynatronics Corporation (DYNT) Reports Q4 Loss, Misses Revenue Estimates
Other News for SARTF
American Century Focused International Growth Fund Q2 2024 Commentary
RGA Investment Advisors Q2 2024 Investment Commentary
BlackRock Health Sciences Term Trust Q2 2024 Commentary
Franklin Growth Fund Q2 2024 Commentary
Invesco International Diversified Fund Q2 2024 Review